remains an alternative to serotype-specific LPS-based vaccines due to their limited use and to antibiotics due to the intrinsic resistance to antimicrobials observed in P. aeruginosa. We have chosen a monoclonal Ab (MAb), MF23-1, that binds to the O antigen of the most clinically relevant serotype, IATS O6, for producing a recombinant antibody. Heavy (H) and light (L) chain genes were isolated from MF23-1 to form a functional Fab molecule in the periplasm of Escherichia coli and on the surface of phage by using phagemid vector pComb3. The entire L chain gene was used, but the H chain gene was amplified to 2 amino acids past cysteine 128 which is involved in interchain disulfide bond formation with the L chain. The truncated H chain associated with the L chain in the periplasm of E. coli to form a functional Fab molecule that bound in both enzyme-linked immunosorbent assay (ELISA) and immunofluorescence assay to O6 LPS. Therefore, the remainder of the C H 1 past cysteine 128 is not essential for stable formation of the Fab portion of MF23-1. This recombinant Fab (r-Fab) was shown to be specific for the LPS of the most predominant clinical isolate, serotype O6, while no cross-reactivity was detected to the LPS of the other 19 remaining serotypes. This r-Fab was also expressed on the surface of filamentous phage upon addition of helper phage to recombinant E. coli containing phagemid. Recombinant phage from clones MT13 and MT24 bound specifically to O6 LPS in ELISA. These results represent an important step toward the design of therapeutic Abs to be used against P. aeruginosa infections.
Pseudomonas aeruginosa is a gram-negative opportunistic organism, infecting immunosuppressed patients, burn victims, and individuals with cystic fibrosis. This organism is also the causative agent in many of the gram-negative septic shock cases reported (5) . P. aeruginosa is resistant to many antibiotics (42) , making chemotherapy an ineffective method of treatment, and lipopolysaccharide (LPS)-based vaccines are limited in their use due to their serotype specificity. Alternatively, passive immunotherapy with antibodies (Abs) has been shown previously to have potential (9, 14, 38) . Monoclonal Abs (MAbs) specific for immunodominant epitopes are preferred to plasma-derived polyclonal antibodies. However, the use of murine MAbs produced through the advances in hybridoma technology (27) can lead to a human anti-mouse Ab response, reducing the therapy's effectiveness (18, 24, 31, 34) . To alleviate this problem, several human MAbs have also been developed to various P. aeruginosa antigens through fusion between a murine myeloma cell line and sensitized human lymphocytes (45, 46, 51) . However, the use of a murine myeloma cell line results in MAbs contaminated with murine cell products. Alternative methods for the production of human MAbs have also been developed by using Epstein-Barr virus-transformed human lymphocytes previously sensitized to P. aeruginosa (29, 36, 50, 55) . In most cases, however, these cell lines are unstable and do not remain an immortal source for Ab production. With the application of recombinant DNA technology to MAb production, however, came an alternative method for production of Abs specific for P. aeruginosa.
LPS, a major component of the outer membrane of gramnegative bacteria, is a significant virulence determinant for P. aeruginosa (10) . LPS consists of three chemically and antigenically distinct regions: O polysaccharide, core oligosaccharide, and lipid A. The core region is further divided into an outer core and an inner core oligosaccharide. Abs to the core oligosaccharide, a more conserved region on the LPS molecule, are more broadly cross-reactive to other serotypes. We have previously expressed in Escherichia coli a recombinant Fab specific for the inner core region of P. aeruginosa, which was found to cross-react with all 20 serotypes of P. aeruginosa as well as other gram-negative organisms (13) . Abs to the O antigen (Ag) have been found to be more effective than Abs to other components of the LPS molecule (32, 45, 46, 49) . However, these Abs are serotype specific, limiting their broad use as immunotherapeutic agents.
Previously in our laboratory, a murine MAb, MF23-1, has been produced which is specific for the O Ag of serotype O6 (28) . Among P. aeruginosa isolates from clinical samples, serotype O6 has been the predominant clinical isolate (39) . Therefore, MF23-1 is a good candidate for the engineering of therapeutic Abs against P. aeruginosa LPS. In this study we have successfully isolated the immunoglobulin (Ig) genes corresponding to the Fab fragment of this hybridoma cell line and expressed them in E. coli and on the surface of phage to produce Fabs which are specific for the O Ag of serotype O6. The strategy for producing this functional Fab is discussed. These results represent the first step toward the design of a therapeutic Ab suitable for humans in the treatment of P. aeruginosa infections.
MATERIALS AND METHODS
Hybridoma cell lines and bacterial strains. Production of the original murine cell line MF23-1 (␥2b/) has been described elsewhere (28) . The V H gene family characterization by Northern blot analysis for the cell line MF23-1 has been previously presented (12) , but the sequence analysis of the V H and V L genes will be presented here.
P. aeruginosa serotypes used in the study were O1 (ATCC 33348), O2 (ATCC 33349), O3 (ATCC 33350), O4 (ATCC 33351), O5 (ATCC 33352), O6 (ATCC 33354), O7 (ATCC 33353), O8 (ATCC 33355), O9 (ATCC 33356), O10 (ATCC 33357), O11 (ATCC 33358), O12 (ATCC 33359), O13 (ATCC 33360), O14 (ATCC 33361), O15 (ATCC 33362), O16 (ATCC 33363), O17 (ATCC 33364), and O18-O20 (30) .
Phagemid expression vectors. The phagemid vector pComb3 used in the expression of the Ig genes from hybridoma MF23-1 was kindly supplied by A. Kang (Scripps Research Institute, La Jolla, Calif.) and has been described in detail elsewhere (2) . The PCR-amplified heavy (H) chain region and light (L) chain were cloned into SpeI/XhoI and SstI/XbaI sites, respectively, in pComb3. The H chain portion of the Fab is expressed as a fusion protein to coat protein III (cpIII) of filamentous phage, while the L chain portion is secreted separately into the periplasmic space. Both the H and L chain genes are under the control of separate lac promoters and are directed to the periplasmic space with the inclusion of a pelB leader sequence in the phagemid vector. When the cpIII is excised from the vector, soluble Fab is expressed into the periplasm of E. coli. However, the addition of helper phage to recombinant E. coli containing phagemid leads to the incorporation of the Fab molecule on the surface of phage during normal phage morphogenesis.
Amplification and sequencing of Ig genes. First-strand cDNA was synthesized with 5 g of total RNA, 11 l of bulk first-strand reaction mix, 1 l of oligo(dT) primer, and 1 l of dithiothreitol from a commercially available kit (Pharmacia, Baie d'Urfe, Quebec, Canada). The complete L chain was amplified by PCR with a 5Ј primer specific for the 5Ј end of V framework region 1 (FR1), GACGAA TTCCGAGCTCCAGATGACCCAGTCTCCA and a 3Ј primer specific for the 3Ј end of the constant (C) region of the chain, CGCCGTCTAGAATTAAC ACTCATTCCTGTTGAA (15, 22, 37) , where the SacI and XbaI sites, respectively, for the cloning of the L chain into pComb3 are underlined. The H chain of MF23-1 was amplified up to amino acid 130, just beyond the cysteine involved in disulfide bond formation with the L chain, by using a universal 5Ј primer, AGGTCCA(G/A)CT(G/T)CTCGAGTC(T/A)GG (22) , which anneals to the FR1 of the H chain and a 3Ј primer, AGGGCTAGCACTAGTA(C/T)CTCCA CACACAGG(A/G)(A/G)CCAGTGGATAGAC (20) , which anneals to the 5Ј region of the C H 1 of IgG, where the XhoI and SpeI restriction sites, respectively, for H chain cloning are underlined. PCR amplification was carried out with 5 l of first-strand cDNA-1.8 mM MgCl 2 -2.0 U of Taq polymerase (Gibco BRL, Burlington, Ontario, Canada)-100 pmol of each primer-0.2 mM each deoxynucleoside triphosphate in 1ϫ PCR buffer (Perkin-Elmer, Norwalk, Conn.). Twenty-five rounds of amplification were carried out by using a GeneAmp PCR System 2400 (Perkin-Elmer) consisting of 1 min of denaturation at 95ЊC, 2 min of annealing at 52ЊC, and 2 min of extension at 72ЊC. Following amplification, the PCR products were isolated from 0.7% low-melting-point agarose gels with Gene Clean (Bio 101 Inc., La Jolla, Calif.) and digested with the corresponding restriction enzymes for cloning into expression vector pComb3 and into Bluescript KS(Ϯ) vector for double-stranded dideoxy sequencing using Sequenase version 2.0 (United States Biochemical, Cleveland, Ohio).
Soluble Fab expression. Our preparation of phagemid DNA for soluble Fab expression and our procedure for soluble Fab expression in the periplasm of E. coli have been described previously (2) with a few minor modifications. Briefly, 250-ml cultures of E. coli containing recombinant phagemids, with the gene III excised, were grown in Luria broth with 50 g of carbenicillin per ml and 20 mM MgCl 2 at 37ЊC until optical density at 600 nm was 0.2, at which time 1 mM IPTG was added. Growth was continued overnight at 30ЊC. The following morning, the supernatant was cleared by centrifugation and the cell pellet was washed twice with 10 mM Tris-HCl, pH 6.8. Cells were then resuspended in 7.5 ml of Trissucrose buffer, where they were then passed through a French pressure cell (American Instrument Company, Silver Spring, Md.) twice at 1,500 lb/in 2 . Cellular debris was pelleted by centrifugation at 1,000 ϫ g for 10 min. The Fabcontaining supernatant was used directly for enzyme-linked immunosorbent assay (ELISA) and Western immunoblot analysis.
Phage display of recombinant Fab. Helper phage VCSM13 (10 12 PFU) (Pharmacia) was added to 100 ml of growing cultures of recombinant E. coli containing phagemids. After 2 h of shaking at 37ЊC, kanamycin (Sigma Chemical Co., St. Louis, Mo.) was added at a concentration of 70 g/ml and growth was continued overnight. Phage precipitation, determination of titer, and panning the phage against antigen-coated ELISA plates have been described elsewhere (2) . The panning procedure was repeated twice for enrichment of LPS-specific phage displaying Fab for analysis.
ELISA. LPS was isolated according to the method of Hitchcock and Brown (16) and was diluted 1:25 in H 2 O. Immulon 2 ELISA plates (Dynatek Laboratories, Chantilly, Va.) were coated with 100 l of diluted LPS and allowed to evaporate overnight at 37ЊC. ELISA plates were blocked with 5% skim milk in phosphate-buffered saline (PBS) for 1 h at room temperature. French press soluble Fab-containing supernatant or phage displaying Fab eluted from the panning procedure was used as a first Ab. The second Ab used for detection of LPS-specific soluble Fab was goat anti-mouse IgG F(abЈ) 2 fragment specific Ab conjugated to alkaline phosphatase, while the second antibody used for detection of LPS-specific phage displaying Fab was an anti-M13 antibody conjugated to horseradish peroxidase, included in a recombinant phage detection kit (Pharmacia). The substrate for alkaline phosphatase was prepared with two p-nitrophenyl phosphate tablets (Sigma Chemical Co.) dissolved in 10 ml of diethanolamine buffer, pH 9.8. The substrate for color development for horseradish peroxidase was 1ϫ ABTS supplied in the recombinant phage detection kit. After each step of the ELISA, the plate was washed 7 times with PBS-Tween in an Automatic Plate Washer (Bio-Tek Instruments, Winooski, Vt.). Color development was monitored after 1 h at 405 nm with a kinetic microplate reader (Molecular Devices, Sunnyvale, Calif.).
Indirect immunofluorescence. A loopful of P. aeruginosa IATS O6 cells was resuspended in 0.5 ml of sterile saline, and 10 l of this bacterial suspension was placed onto slides, air dried, and subsequently heat fixed. The slides were then washed 5ϫ with PBS-Tween and blotted dry. Ten microliters of soluble Fab supernatant was placed on the slide as the first Ab, and the slide was placed in a damp paper towel-lined petri dish in a 37ЊC incubator for 1 h. Slides were again washed 5ϫ with PBS-Tween and blotted dry. Ten microliters of fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse kappa chain Ab (BioCan) diluted 1:50 in saline was used to detect recombinant Fab binding to O6 cells. After 1 h of incubation at 37ЊC with the FITC-conjugated Ab, the slides were washed 5ϫ with PBS-Tween and 10ϫ with H 2 O. Fluorescence was monitored with a Zeiss microscope (Carl Zeiss Canada, Don Mills, Ontario, Canada) with epifluorescence microscopy attachments.
EM of recombinant phage. Due to the presence of pili and flagella in P. aeruginosa cells, it was difficult to distinguish between bacterial pilus and flagellum appendages and filamentous phage displaying the Fab interacting with the cell surface of P. aeruginosa. Thus, membrane vesicles of the bacterial cells were prepared to facilitate the examination of the phage and P. aeruginosa interactions.
(i) Membrane vesicle labelling. A 200-mesh, Formvar-and carbon-coated copper electron microscopy (EM) grid was floated on a drop of recombinant phage (10 11 PFU/ml) which was mixed 1:1 with isolated outer membrane vesicles from P. aeruginosa serotype O6 for 45 s to allow particulate matter to absorb to the grid. Isolation of membrane vesicles and demonstration of LPS on its outer surface has been described previously by Kadurugamuwa and Beveridge (21) . The grid was blotted dry and any PBS buffer was washed from the grid face by successive washes in deionized water. After being blotted dry, the grid was floated on 2% (wt/vol) aqueous uramyl acetate for 15 s and blotted dry. Control grids of the phage and the vesicles were prepared separately to prove that no contaminating particulate matter was present. All grids were examined with a Philips EM300 transmission electron microscope operating at 60 kV under standard conditions with the cold trap in place.
(ii) Immunogold labelling of recombinant phage. Goat anti-mouse IgG F(abЈ) 2 specific Ab labelled with a 15-nm colloidal gold particle (EY Laboratories, San Mateo, Calif.) was diluted to 2 g of protein per ml so that the phage-to-gold ratio was approximately 1:100. This ensured that most gold particles would be attached to the phage. EM grids were floated on this mixture and processed as described previously for the phage-vesicle experiments. For controls, the following experiments were performed: (i) unlabelled colloidal gold, (ii) phage and gold processed separately, and (iii) attempted labelling of a nonrecombinant phage.
Nucleotide sequence accession numbers. The sequence accession number for V H is GenBank accession number U62777, and that for V L is GenBank accession number U62776.
RESULTS

PCR amplification of V H and chain genes. Isolation of the
Ig genes from hybridoma MF23-1 represents the first step in the cloning of the H and L chain genes corresponding to an Fab into phagemid vector pComb3. Figure 1 shows gel-purified PCR products of V H and chains amplified from hybridoma MF23-1 first-strand cDNA. Two bands are visible at approximately 390 bp for the V H PCR product, which corresponds to a truncated H chain component of an Fab, extending 2 amino acids past the cysteine involved in interchain disulfide bond formation to the L chain. The upper band was later identified as the correct V H PCR product through Southern blot analysis with the V H J606 gene family probe, previously identified for the cell line MF23-1 (12) . The L chain PCR product corresponds to the expected size of the complete L chain (680 bp). The V H and L chains were subsequently digested with SpeI/ XhoI and SstI/XbaI, respectively, and cloned into pComb3, where phagemid DNA was monitored for V H and insertion by hybridizing digested plasmid preparations with a V H J606 family-specific probe and a constant region probe from the chain, respectively (data not shown).
Sequence analysis. The variable (V) region protein sequences corresponding to the L and H chains have been aligned for comparison with the top five homologous sequences from the GenBank databases (Fig. 2) . Nucleotide sequences for both the H and L chain genes have been submitted to GenBank under accession numbers U62777 and U62776. The top five homologous sequences to MF23-1 V were O25G3D6 V (accession number U25098) (100%) (12), another Ab specific for serotype O6 LPS previously characterized in our laboratory, an anti-lysozyme Ab, Gloop 1 V (accession number X02177) (97%) (11) , an anti-DNA Ab, 202.105 V (accession number Z22118) (92%) (52) , an antinitrophenyl phosphonate catalytic Ab, CNJ206 V (accession number S69053) (97%) (54) , and an Ab isolated from systemic lupus erythematosus (SLE) patients, MRL2-117 V (accession number U19320) (98%) (44) . All six L chains in Fig. 2a are conserved in the FRs and in the complementarity-determining region 1 (CDR1). CDR2 is well conserved among these Abs, while the only significant variation occurs in CDR3, where three out of the nine amino acid positions vary. The V region corresponding to MF23-1 is formed between a member of the V 9 family and a germ line J 5 gene.
The top five homologous sequences to the MF23-1 V H gene are aligned in Fig. 2b , corresponding to the cell line 17p.3 V H (accession number Z22076) (92%) (52) specific for DNA, antihistone Ab, NZA3 V H (accession number X63804) (95.5%) (35) , an anti-pre-S2 Ag of hepatitis B virus hybridoma H8 V H (accession number M98041) (95.5%) (17), the V H region from hybridoma 19.9 (accession number S65761) (90%) (53), which is glycoprotein CANAG-50 specific, and the V H region from cell line 1E10, secreting auto-Abs reactive with erythrocytes (accession number X51846) (89%) (43) . All six Abs are perfectly conserved in CDR1 and show high similarity in CDR2. However, the CDR3 region is highly variable. The V H region corresponding to MF23-1 is formed between a member of the V H J606 family, a D region (not determined), and a J H 3 gene.
Analysis of Fab expression. Fab expression in E. coli was monitored from three clones designated MT13, MT15, and MT24, which still contain the cpIII in the phagemid DNA leading to a fusion protein between the cpIII of M13 and the H chain. Such a construct leads to incorporation of the H chain fusion protein into the inner membrane of E. coli. Soluble Fab expression was also monitored from two different clones, designated MT15-S3 and MT24-S1, where the cpIII has been excised from the phagemid leading to periplasmic expression in E. coli. The French-pressed supernatant from each of these induced clones was electrophoresed on a 12.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) kDa. This size is larger than expected for a truncated Fab alone due to the fusion of the H chain with the cpIII. In comparison, samples MT15-S3 and MT24-S1 showed expression of a lowermolecular-weight truncated Fab of the expected size (39 kDa), where the Fab is expressed in a soluble form in the periplasm, not in association with cpIII.
Recombinant Fab specific for lipopolysaccharide. Frenchpressed supernatant from induced E. coli cells containing recombinant phagemids was used as a first Ab in an ELISA to test binding to P. aeruginosa serotype O6 LPS. All five Fabexpressing clones, three as fusion proteins to the cpIII inserted in the inner membrane and two in the periplasm of E. coli, showed strong binding to P. aeruginosa serotype O6 LPS. The result of this binding is shown in Fig. 4 for two of these clones, one representing a fusion protein to cpIII (MT15) and one representing a soluble Fab form (MT15-S3). Both clones showed strong binding specifically for O6 LPS. Hybridoma supernatant from the original cell line, MF23-1, was used as a positive control, showing significant binding to O6 LPS, whereas E. coli containing phagemid with no Ig genes inserted (pComb3) used as a negative control showed no binding to O6 LPS. This binding detected for r-Fab clones MT15 and MT15-S3 and for positive control MF23-1 was shown to be specific for serotype O6 LPS, with no binding detected to LPS from the remaining 19 serotypes (Fig. 4) .
Binding of r-Fab to LPS on whole cells of P. aeruginosa serotype O6 was also investigated by fluorescence microscopy   FIG. 3 . Western immunoblot analysis of soluble Fab and cpIII-Fab fusions from French-pressed supernatants of recombinant E. coli containing phagemid. A 10-l amount of supernatant was boiled for 10 min prior to separation on a 12.5% nonreducing SDS-PAGE gel followed by a Western transfer to nitrocellulose. Fab fragments were detected by using a goat anti-mouse F(abЈ) 2 -alkaline phosphatase-conjugated Ab. A Bio-Rad protein marker has been included in the first lane for size comparisons. Samples MT13, MT15, and MT24 represent fusion protein r-Fabs whereby the H chain is fused to the cpIII, which is inserted into the inner membrane of E. coli. Samples MT15-S3 and MT24-S1 represent soluble Fab clones, whereby the cpIII is excised from the construct, leading to secretion into the periplasm. using a goat anti-mouse kappa Ab conjugated to FITC as a second Ab. Phase-contrast light microscopy panels (panels B, D, and F) are presented in parallel with fluorescence microscopy panels (panels A, C, and E) for comparison in Fig. 5 . No fluorescence was detected when E. coli containing vector alone (pComb3) French-pressed supernatant was used as a primary Ab (panel E). Hybridoma supernatant from MF23-1, the original cell line, was used as a positive control and strong immunofluorescence is clearly discerned (panel A). The recombinant soluble Fab, MT24-S1, also interacted strongly with the cells of P. aeruginosa O6 (panel C). Interestingly, the level of immunofluorescence of this r-Fab is comparable to that observed in the MAb MF23-1 (panel A). Every cell that is observed under phase-contrast microscopy (panel D) shows up well by immunofluorescence microscopy when incubated with the r-Fab (panel C). The binding activity of the recombinant Ab was shown to be specific for LPS of serotype O6. No fluorescence was observed with cells from P. aeruginosa serotype O5 (data not shown).
Specificity of recombinant phage for P. aeruginosa serotype O6 LPS. Helper phage was added to recombinant clones MT13 and MT24 and to pComb3 containing no Ig genes, leading to incorporation of Fabs on the surface of phage during its normal morphogenesis cycle. Recombinant phage was then put through two rounds of panning on O6 LPS-coated ELISA plates to isolate O6 LPS-specific recombinant phage. Eluted phage from the second round of panning was used as a first Ab in an ELISA using an anti-M13 Ab conjugated to horseradish peroxidase as a second Ab. Results of the interaction of recombinant phage with LPS from serotype O6 of P. aeruginosa FIG. 5 . Immunofluorescence microscopy of the binding of soluble r-Fab to P. aeruginosa O6 cells. An FITC-conjugated goat anti-mouse kappa chain was used as a second antibody. (A, C, and E) Fluorescence microscopy shots in parallel; (B, D, and F) equivalent phase-contrast microscopy shots. Hybridoma supernatant from MF23-1 used as a positive control is shown in panels A and B, while the soluble r-Fab from clone MT24-S1 used as a first Ab is shown in panels C and D. A primary Ab using supernatant from vector alone, clone pComb3, was used as a negative control and is shown in panels E and F.
VOL. 4, 1997 P. AERUGINOSA LPS-SPECIFIC RECOMBINANT Fab 151 are illustrated in Fig. 6 . Strong binding of recombinant phage clones MT13 and MT24 to serotype O6 LPS was observed, and no binding was observed to LPS from serotype O5 used as a control. Filamentous phage from negative control phagemid containing no Ig genes, designated pComb3, also did not show any binding to O6 LPS. EM of phage displaying Fab. Recombinant phage were tested for their Fab expression as a fusion protein with cpIII at the tip of filamentous phage. Specific labelling of the recombinant phage with a colloidal gold-labelled anti-IgG Fab-specific Ab was seen at the infection tip where the cpIII-Fab fusion resides (Fig. 7a and b ). All controls, described in Materials and Methods, were negative. There are five copies of cpIII on the tip of filamentous phage. Wild-type cpIII from the helper phage competes with the Fab-cpIII fusion from the phagemid for incorporation into phage particles, leading to expression of two forms of cpIII. Therefore, more than one Fab-cpIII fusion protein can be incorporated into the phage particle, as seen in Fig. 7b . However, on average, one Fab is displayed per phage particle. The majority of the labelling showed a single gold particle at the infectivity tip (Fig. 7a) .
Binding of recombinant phage to P. aeruginosa O6 membrane vesicles was also observed under EM. Specific binding of recombinant phage to O6 membrane vesicles with LPS on its outer surface was observed (Fig. 7c) . The binding of the recombinant phage to the O6 vesicles was seen at the infection tip, where the cpIII-Fab resides, and not to other areas along the surface of phage. Binding of control nonrecombinant phage to the vesicles could not be discerned (data not shown).
DISCUSSION
Amplification of Ig H and L genes from existing characterized hybridomas by PCR (37) and the development of prokaryotic expression vectors for secretion of functional Fabs in the periplasmic space of E. coli (4, 48) and on the surface of phage (3, 8, 23, 33) have advanced the field of immunotherapy. Ab molecules can now be manipulated and studied with much more ease, paving the way for engineering of high-affinity therapeutic Abs. Engineering of Abs that bind to immunodominant epitopes of P. aeruginosa such as LPS is an alternative to chemotherapy due to the increase of multidrug-resistant strains (41) . We have chosen an MAb, MF23-1, that binds to the O Ag of the most clinically relevant serotype, IATS O6, to isolate the H and L chain genes to form a functional Fab molecule in the periplasm of E. coli and on the surface of phage. The entire L chain gene was used, but the H chain gene was amplified to two amino acids past cysteine 128, which is involved in interchain disulfide bond formation with the L chain (Fig. 1) . This alternative to formation of an Fab was used to overcome the problem of cloning of irrelevant Ig genes frequently encountered in the cloning of Ig genes from hybridoma cells (unpublished results). Amplification of the H chain portion of an Fab (Fd) including the entire C H 1 region (approximately 700 bp) frequently led to the cloning of irrelevant bands of the same size which did not react with the V H J606 FIG. 6 . ELISA detection of r-Fab displayed on the surface of phage. Recombinant phage recovered after two rounds of panning on an O6 LPS-coated ELISA plate was used as a first Ab, and an anti-M13 Ab conjugated to horseradish peroxidase was used as a second Ab. Two recombinant phage clones (MT13 and MT24) were tested for their abilities to bind to O6 LPS and O5 LPS, used as a negative control LPS sample. A phage sample derived from a phagemid vector alone control was used as a negative control. The numbers represent the means from the ELISA done in triplicate. Standard error bars are shown. family-specific probe, previously identified for our cell line MF23-1. As is most often the case, nonproductive Ig mRNA could be present at a high concentration and thus serve as an effective substrate for PCR (6) . Alternatively, amplification of the H chain with primers just beyond the 128 Cys involved in the interchain disulfide bond, resulting in a product of approximately 400 bp in size, led to cloning of the correct product reactive with our V H J606 family-specific probe. The idea that a stable Fab could be formed by using a truncated H chain C H 1 was initiated from a report from Alfthan and coworkers (1), who found that deletion of most of the C-terminal part of the C H 1 region except the Cys 128 H participating in the interchain disulfide bond formation led to functional assembly with the L chain and formation of the interchain disulfide bond. Therefore, most of the C H 1 region is absent, but the interchain disulfide bond between the H and L chains can still form, resulting in a stable association between the two chains. Association between the truncated H chain portion and the L chain to form an Fab was confirmed through Western immunoblotting with a goat anti-mouse F(abЈ) 2 alkaline phosphatase-conjugated Ab (Fig. 3) . Under nonreducing conditions, the predominant upper band corresponds to the expected size of a truncated H chain in disulfide bond association with the L chain (50 and 39 kDa). The lower band (25 kDa) corresponds to excess unassociated L chain. Therefore, our results showed that the remainder of the amino acids past cysteine 128 are not essential for stable formation of the Fab portion of MF23-1. The proper folding of the antigen binding site of the truncated Fab from MF23-1 also seemed unaffected, as French-pressed supernatant of E. coli cultures containing Fab from recombinant clones showed significant binding to O6 LPS in ELISA (Fig. 4) and in immunofluorescence microscopy studies (Fig.  5) . This binding was shown to be specific for the LPS of the most predominant clinical isolate, serotype O6, while no crossreactivity was detected to the LPS of the other 19 remaining serotypes.
Phage display of Ab fragments continues to be a powerful means of selection of high-affinity binders. The Fab from our O6 LPS specific MAb was displayed successfully as a fusion protein with cpIII at the tip of filamentous phage ( Fig. 7a and  b) . This recombinant phage displaying Fab at its surface was specific for P. aeruginosa O6 LPS both in ELISA (Fig. 6 ) and under EM with O6 membrane vesicles (Fig. 7c) . Our future work will focus on the mutagenesis of these anti-LPS Ig H and L chain V region genes with the help of phage display to improve the affinity of anti-carbohydrate Abs and to probe the regions which influence binding to LPS.
One drawback associated with the cloning and expression of Ig genes from existing hybridomas is the reduction in valency associated with expression of monovalent Fabs from bivalent IgG molecules and IgM pentamers. This monovalency can lead to a reduction in binding affinity, especially in the case of cloning of Ig genes from IgM MAbs (unpublished observation). However, in the case of MF23-1, the original hybridoma, the isotype is IgG2b. Although significant binding of this recombinant monovalent Fab to O6 LPS was detected in both ELISA and immunofluorescence studies, very low levels of binding have been noted for other recombinant anti-LPS Fabs constructed from hybridomas of the IgM isotype (53a). Expression of Ig genes in a dimeric single-chain Ab system is presently being investigated to improve on the avidity of IgM anti-LPS Abs (53a).
The O Ag of serotype O6 is an important target for therapeutic Abs due to the predominance of this clinical serotype. One of the first steps involved in this process is an examination of the V region genes which dictate the three-dimensional structure the Ag-binding site will take. The nonrestricted V region gene usage found for V H and V L genes isolated from various hybridomas specific for P. aeruginosa LPS may in fact be due to its heterogeneous nature, consisting of several unique polysaccharide epitopes (12) . The O Ag of IATS O6 is composed of tetrasaccharide repeating units of L-rhamnose, N-acetyl-D-quinovosamine, N-formyl-D-galactosaminuronamide, and N-acetyl-D-galactosaminuronamide (25) . The V region gene isolated from MF23-1, specific for this O Ag, is identical to a chain gene from another Ab produced in our laboratory during a separate fusion procedure, 025G3D6, that also has specificity to O6 O Ag. Although these two MAbs, MF23-1 and 025G3D6, share identical L chains, we have found in a previous study that their H chains are very diverse, belonging to two different V H gene family groups, V H J606 and SM7, respectively (12) . It is interesting that through two separate fusion procedures between NS-1 myeloma cells and O6 LPS immunized spleen cells, the identical L chain was used in combination with two different H chain genes to form MAbs with similar binding patterns. This suggests an important structural role for the L chain in forming the Ag-binding site for O6 LPS. In a recent report by Pollack and coworkers, the sequences from the H and L chain variable regions from another anti-O6 LPS-specific MAb were reported (40) . However, our anti-O6 LPS V H and V L chain genes showed little homology (60%) to these Ig genes, indicative of a diversified immune response to the complex O polysaccharide. Other significant homologies to the L chain of MF23-1 were L chains from Abs isolated from SLE patients, an anti-nitrophenyl phosphonate catalytic Ab, an antilysozyme Ab, and an anti-DNA Ab. Other Ig variable region genes have been found to encode both pathogenic and protective Abs, and the same MAb may bind to an autoantigen, to DNA, and to microbial antigens (7, 19, 26, 47) . This conservation in sequence between anti-DNA Abs and antibacterial polysaccharides was not only seen with the L chain; the V H sequence from MF23-1 is also highly homologous to the V H region from another anti-DNA Ab.
Future steps toward design of a therapeutic Ab in the treatment of P. aeruginosa infections include mutagenesis of the V region genes to detect higher-affinity Fabs using phage display and cloning of these Ig genes into a chimeric vector system designed to add a human constant region to the variable region genes, thus minimizing the murine components of these Abs. The protective nature of these recombinant Abs will be closely monitored as the Fab portions of our anti-LPS Abs are fused to human constant regions of varying isotypes. Previous studies on another LPS-specific Ab suggested using a cautious approach when choosing a particular Ig class and subclass for immunotherapeutics where isotype-related differences in levels of the efficiency of various effector functions did not correspond to differences in in vivo function (40) . In conclusion, results from this study have helped to shed some light on the technology of construction of a functional Fab. These results represent an important step toward the design of Abs that have potential in intervention against P. aeruginosa infections.
